E3 Ligase Ligand-Linker Conjugate
Read More about this categoryShow Less
E3 Ligase Ligand-Linker Conjugate, which is one part of Proteolysis Targeting Chimeric Molecules (PROTACs), incorporates a ligand for the E3 ubiquitin ligase and a linker. After linked to the ligand for target protein (such as JQ1 for BRD4 protein, Molibresib for BET protein), those conjugates can be used for constituting PROTACs that targetprotein for ubiquitination and degradation. Currently, several PROTACs have been found to show good biological activity by specifically targeting BET, estrogen receptor (ER), androgen receptor, etc.MedChemExpress (MCE) offers a wide range of high quality E3 Ligase Ligand-Linker Conjugates including von Hippel-Lindau (VHL) ligands, MDM2 ligands, Cereblon (CRBN) ligands and cIAP1 ligands conjugating with different linkers (PEGs, Alkyl-Chain, Alkyl/ether, etc.). It’s convenient and time-saving for designing and synthesizinga wide variety of novel PROTACs (ARV-825, dBET1,MT-802, etc.), which can expand the application of PROTACs in the treatment of cancer, autoimmunity, inflammation and other diseases.
Products Related to E3 Ligase Ligand-Linker Conjugate(201)
- GC67508Thalidomide-NH-C4-NH2 TFACAS: 2093387-50-7Purity: >98%
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 . PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader.
- GC67530Thalidomide-NH-C10-COOHCAS: 2428400-33-1Purity: >98%
Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology.
- GC67606Thalidomide-O-amido-PEG-C2-NH2CAS: 2022182-59-6Purity: >98%
Thalidomide-O-amido-PEG-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
- GC68839Cbl-b-IN-2CAS: 2503325-21-9Purity: >98%
Cbl-b-IN-2 (Example 8) is an orally effective bioactive compound that inhibits the E3 enzyme Casitas b-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin-proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases that are susceptible to immune system regulation. Cbl-b-IN-2 (Example 8) can also be used alone or in combination with one or more immune checkpoint inhibitors, anti-tumor agents, and radiation for cancer treatment.
- GC69726Pomalidomide-5'-PEG8-C2-COOHCAS: 2138440-78-3Purity: >98%
Pomalidomide-5'-PEG8-C2-COOH is an E3 ligase ligand-linker conjugate composed of Pomalidomide and a linker. It can be used to synthesize PROTACs.
- GC69727Pomalidomide-PEG1-NH2 hydrochlorideCAS: 2380273-67-4Purity: >97.00%
Pomalidomide-PEG1-NH2 hydrochloride is a crosslinking E3 ligase ligand conjugate composed of the E3 ligase ligand pomalidomide and a PEGylated crosslinker with an end amine group, which is used to react with carboxylic acid groups on the target ligand.
- GC69743(S,R,S)-AHPC-C4-NH2 hydrochlorideCAS: 2245697-83-8Purity: >97.00%
(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, containing a VHL ligand based on (S,R,S)-AHPC and one linker. It is used for the synthesis of targeted PROTACs for EED.
- GC69944(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFACAS: 2417370-89-7Purity: >95.00%
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFA is a synthetic E3 ligase ligand-linker conjugate containing the (S,R,S)-AHPC ligand, which can be used in PROTAC research.
- GC69945(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFACAS: 2417370-48-8Purity: >99.00%
"(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA" is a synthetic E3 ligase ligand-linker conjugate, which includes a ligand based on (S,R,S)-AHPC and a three-unit PEG linker."
- GC69946(S,R,S)-AHPC-amido-C7-acidCAS: 2172819-76-8Purity: >98.00%
(S,R,S)-AHPC-amido-C7-acid contains a VHL ligand for recruiting E3 ubiquitin ligases and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used for designing PROTACs.
- GC69947(S,R,S)-AHPC-C10-NHBocCAS: 2412055-13-9Purity: >98.00%
(S,R,S)-AHPC-C10-NHBoc is a synthetic E3 ligase ligand-linker conjugate, containing a VHL ligand based on (S,R,S)-AHPC and one linker. It can be used to synthesize targeted PROTACs for BET.
- GC69948(S,R,S)-AHPC-CO-C9-acidCAS: 2172819-78-0Purity: >98%
"(S,R,S)-AHPC-CO-C9-acid" is a ligand-linker complex of E3 ligase, which can be attached to the ligand of a protein to form a PROTAC."
- GC70023Thalidomide-5-PEG4-NH2 hydrochlorideCAS: 2743434-24-2Purity: >98%
Thalidomide-5-PEG4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, containing a cereblon ligand based on Thalidomide and one linker.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC67508 | Thalidomide-NH-C4-NH2 TFA | 2093387-50-7 | >98% | |
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 . PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader. | ||||
| GC67530 | Thalidomide-NH-C10-COOH | 2428400-33-1 | >98% | |
Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology. | ||||
| GC67606 | Thalidomide-O-amido-PEG-C2-NH2 | 2022182-59-6 | >98% | |
Thalidomide-O-amido-PEG-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. | ||||
| GC67729 | (S,R,S)-AHPC-Me-C6-NH2 | 2411422-49-4 | >98% | |
| GC67740 | Thalidomide-PEG5-NH2 hydrochloride | 2703775-06-6 | >98% | |
| GC67741 | Thalidomide-PEG2-NH2 hydrochloride | - | >95.00% | |
| GC67827 | Thalidomide-O-C6-NHBoc | 2509093-23-4 | >98% | |
| GC67831 | (S,R,S)-AHPC-Me-C10-Br | 2836297-55-1 | >97.00% | |
| GC67980 | VH285-PEG4-C4-Cl | 1799506-07-2 | - | |
| GC67991 | Nutlin-C1-amido-PEG4-C2-N3 | - | >96.00% | |
| GC68155 | Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc | 1799711-31-1 | >98% | |
| GC68156 | Pomalidomide-amino-PEG3-NH2 hydrochloride | 2380273-75-4 | >99.00% | |
| GC68157 | Pomalidomide-amino-PEG5-NH2 hydrochloride | 2421217-05-0 | >99.00% | |
| GC68431 | NJH-2-030 | 2709040-02-6 | >98% | |
| GC68839 | Cbl-b-IN-2 | 2503325-21-9 | >98% | |
Cbl-b-IN-2 (Example 8) is an orally effective bioactive compound that inhibits the E3 enzyme Casitas b-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin-proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases that are susceptible to immune system regulation. Cbl-b-IN-2 (Example 8) can also be used alone or in combination with one or more immune checkpoint inhibitors, anti-tumor agents, and radiation for cancer treatment. | ||||
| GC69726 | Pomalidomide-5'-PEG8-C2-COOH | 2138440-78-3 | >98% | |
Pomalidomide-5'-PEG8-C2-COOH is an E3 ligase ligand-linker conjugate composed of Pomalidomide and a linker. It can be used to synthesize PROTACs. | ||||
| GC69727 | Pomalidomide-PEG1-NH2 hydrochloride | 2380273-67-4 | >97.00% | |
Pomalidomide-PEG1-NH2 hydrochloride is a crosslinking E3 ligase ligand conjugate composed of the E3 ligase ligand pomalidomide and a PEGylated crosslinker with an end amine group, which is used to react with carboxylic acid groups on the target ligand. | ||||
| GC69743 | (S,R,S)-AHPC-C4-NH2 hydrochloride | 2245697-83-8 | >97.00% | |
(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, containing a VHL ligand based on (S,R,S)-AHPC and one linker. It is used for the synthesis of targeted PROTACs for EED. | ||||
| GC69944 | (S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFA | 2417370-89-7 | >95.00% | |
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFA is a synthetic E3 ligase ligand-linker conjugate containing the (S,R,S)-AHPC ligand, which can be used in PROTAC research. | ||||
| GC69945 | (S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA | 2417370-48-8 | >99.00% | |
"(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA" is a synthetic E3 ligase ligand-linker conjugate, which includes a ligand based on (S,R,S)-AHPC and a three-unit PEG linker." | ||||
| GC69946 | (S,R,S)-AHPC-amido-C7-acid | 2172819-76-8 | >98.00% | |
(S,R,S)-AHPC-amido-C7-acid contains a VHL ligand for recruiting E3 ubiquitin ligases and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used for designing PROTACs. | ||||
| GC69947 | (S,R,S)-AHPC-C10-NHBoc | 2412055-13-9 | >98.00% | |
(S,R,S)-AHPC-C10-NHBoc is a synthetic E3 ligase ligand-linker conjugate, containing a VHL ligand based on (S,R,S)-AHPC and one linker. It can be used to synthesize targeted PROTACs for BET. | ||||
| GC69948 | (S,R,S)-AHPC-CO-C9-acid | 2172819-78-0 | >98% | |
"(S,R,S)-AHPC-CO-C9-acid" is a ligand-linker complex of E3 ligase, which can be attached to the ligand of a protein to form a PROTAC." | ||||
| GC70023 | Thalidomide-5-PEG4-NH2 hydrochloride | 2743434-24-2 | >98% | |
Thalidomide-5-PEG4-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, containing a cereblon ligand based on Thalidomide and one linker. | ||||